关注
Vanessa Roldán (ORCID: 0000-0002-4945-6602)
Vanessa Roldán (ORCID: 0000-0002-4945-6602)
Catedrático de Universidad de Hematologia. Universidad de Murcia
在 um.es 的电子邮件经过验证
标题
引用次数
引用次数
年份
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
J Steffel, P Verhamme, TS Potpara, P Albaladejo, M Antz, L Desteghe, ...
European heart journal 39 (16), 1330-1393, 2018
32312018
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
H Heidbuchel, P Verhamme, M Alings, M Antz, HC Diener, W Hacke, ...
Ep Europace 17 (10), 1467-1507, 2015
14692015
Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting
F Marín, DA Pascual, V Roldán, JM Arribas, M Ahumada, PL Tornel, ...
The American journal of cardiology 97 (1), 55-60, 2006
3252006
Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy
V Roldán, F Marín, H Fernández, S Manzano-Fernandez, P Gallego, ...
Chest 143 (1), 179-184, 2013
2812013
The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial …
V Roldán, F Marín, S Manzano-Fernández, P Gallego, JA Vílchez, ...
Journal of the American College of Cardiology 62 (23), 2199-2204, 2013
2482013
Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC working group …
C Sticherling, F Marin, D Birnie, G Boriani, H Calkins, GA Dan, M Gulizia, ...
Ep Europace 17 (8), 1197-1214, 2015
2392015
Soluble E-selectin in cardiovascular disease and its risk factors
V Roldán, F Marín, GYH Lip, AD Blann
Thrombosis and haemostasis 90 (12), 1007-1020, 2003
2292003
Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation
P Gallego, V Roldan, F Marín, M Romera, M Valdés, V Vicente, GYH Lip
Thrombosis and haemostasis 110 (12), 1189-1198, 2013
2192013
Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, Sedar, Seacv, Sectcv, Aec, Secpre, Sepd, Sego, Sehh, Seth, Semergen, Semfyc …
D Vivas, I Roldan, R Ferrandis, F Marin, V Roldan, A Tello-Montoliu, ...
Revista Española de Cardiología (English Edition) 71 (7), 553-564, 2018
191*2018
Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation
V Roldán, F Marín, AD Blann, A García, P Marco, F Sogorb, GYH Lip
European heart journal 24 (14), 1373-1380, 2003
1902003
Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation
P Gallego, V Roldán, JM Torregrosa, J Gálvez, M Valdés, V Vicente, ...
Circulation: Arrhythmia and Electrophysiology 5 (2), 312-318, 2012
1892012
Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients
V Roldán, F Marín, B Muiña, JM Torregrosa, D Hernández-Romero, ...
Journal of the American College of Cardiology 57 (25), 2496-2504, 2011
1692011
SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation
P Gallego, V Roldán, F Marin, J Gálvez, M Valdés, V Vicente, GYH Lip
The American journal of medicine 127 (11), 1083-1088, 2014
1682014
A multimarker risk stratification approach to non‐ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro‐BNP and fibrin D‐dimer levels
A Tello‐Montoliu, F Marin, V Roldán, L Mainar, MT López, F Sogorb, ...
Journal of internal medicine 262 (6), 651-658, 2007
1512007
Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding)
V Roldán, F Marín, H Fernández, S Manzano-Fernández, P Gallego, ...
The American journal of cardiology 111 (8), 1159-1164, 2013
1452013
High sensitivity cardiac troponin T and interleukin‐6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation
V Roldan, F Marin, J Diaz, P Gallego, E Jover, M Romera, ...
Journal of Thrombosis and Haemostasis 10 (8), 1500-1507, 2012
1412012
Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis
J Corral, D Hernandez-Espinosa, JM Soria, R Gonzalez-Conejero, ...
Blood 109 (10), 4258-4263, 2007
1412007
Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation
F Marin, V Roldan, VE Climent, A Ibanez, A Garcia, P Marco, F Sogorb, ...
Heart 90 (10), 1162-1166, 2004
1352004
Pharmacogenetics in cardiovascular antithrombotic therapy
F Marín, R González-Conejero, P Capranzano, TA Bass, V Roldán, ...
Journal of the American College of Cardiology 54 (12), 1041-1057, 2009
1332009
Premature myocardial infarction: clinical profile and angiographic findings
J Pineda, F Marín, V Roldán, J Valencia, P Marco, F Sogorb
International journal of cardiology 126 (1), 127-129, 2008
1272008
系统目前无法执行此操作,请稍后再试。
文章 1–20